RxDoctor Payments Data

Benjamin Robey, MD

Gastroenterology · Raleigh, NCNPI 1043607203

Payments from drug & device makers

$6,575in general payments, 2019–2025

Across 294 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$418
  • Biotronik NRO, Inc.$385
  • Lilly USA, LLC$362
  • Pfizer$313
  • plus $2K from 28 others

What the payments were for

  • Consulting fees$1,20018%
  • Food & beverage$5,26580%
  • Education$971%
  • Gifts$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,575 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$95,300
Medicare patients
177
Services billed
4,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase14$53,473
LinzessLinaclotide41$27,410
Dexlansoprazole DrDexlansoprazole16$9,269
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates58$3,798
Omeprazole91$1,178
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg53$1,075
Rabeprazole Sodium11$888
Sucralfate26$685
Pantoprazole Sodium20$211
Ondansetron Hcl95$175
Famotidine12$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,672$80,88255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →